Literature DB >> 18615595

Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes.

Michael Menconi1, Patricia Gonnella, Victoria Petkova, Stewart Lecker, Per-Olof Hasselgren.   

Abstract

Dexamethasone-treated L6 (a rat cell line) and C2C12 (a mouse cell line) myotubes are frequently used as in vitro models of muscle wasting. We compared the effects of different concentrations of dexamethasone and corticosterone (the naturally occurring glucocorticoid in rodents) on protein breakdown rates, myotube size, and atrogin-1 and MuRF1 mRNA levels in the two cell lines. In addition, the expression of the glucocorticoid receptor (GR) and its role in glucocorticoid-induced metabolic changes were determined. Treatment with dexamethasone or corticosterone resulted in dose-dependent increases in protein degradation rates in both L6 and C2C12 myotubes accompanied by 25-30% reduction of myotube diameter. The same treatments increased atrogin-1 mRNA levels in L6 and C2C12 myotubes but, surprisingly, upregulated the expression of MuRF1 in L6 myotubes only. Both cell types expressed the GR and treatment with dexamethasone or corticosterone downregulated total cellular GR levels while increasing nuclear translocation of the GR in both L6 and C2C12 myotubes. The GR antagonist RU38486 inhibited the dexamethasone- and corticosterone-induced increases in atrogin-1 and MuRF1 expression in L6 myotubes but not in C2C12 myotubes. Interestingly, RU38486 exerted agonist effects in the C2C12, but not in the L6 myotubes. The present results suggest that muscle wasting-related responses to dexamethasone and corticosterone are similar, but not identical, in L6 and C2C12 myotubes. Most notably, the regulation by glucocorticoids of MuRF1 and the role of the GR may be different in the two cell lines. These differences need to be taken into account when cultured myotubes are used in future studies to further explore mechanisms of muscle wasting. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615595      PMCID: PMC2901105          DOI: 10.1002/jcb.21833

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  60 in total

Review 1.  Post burn muscle wasting and the effects of treatments.

Authors:  Clifford Pereira; Kevin Murphy; Marc Jeschke; David N Herndon
Journal:  Int J Biochem Cell Biol       Date:  2005-10       Impact factor: 5.085

2.  Glucocorticoids and serotonin alter glucocorticoid receptor mRNA levels in fetal guinea-pig hippocampal neurons, in vitro.

Authors:  P Erdeljan; M H Andrews; J F MacDonald; S G Matthews
Journal:  Reprod Fertil Dev       Date:  2005       Impact factor: 2.311

3.  Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle.

Authors:  Curtis J Wray; Joshua M V Mammen; Dan D Hershko; Per-Olof Hasselgren
Journal:  Int J Biochem Cell Biol       Date:  2003-05       Impact factor: 5.085

4.  Rapid activation of ERK1/2 mitogen-activated protein kinase by corticosterone in PC12 cells.

Authors:  J Qiu; P Wang; Q Jing; W Zhang; X Li; Y Zhong; G Sun; G Pei; Y Chen
Journal:  Biochem Biophys Res Commun       Date:  2001-10-05       Impact factor: 3.575

5.  Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway.

Authors:  Esther Latres; Ami R Amini; Ashley A Amini; Jennifer Griffiths; Francis J Martin; Yi Wei; Hsin Chieh Lin; George D Yancopoulos; David J Glass
Journal:  J Biol Chem       Date:  2004-11-17       Impact factor: 5.157

6.  IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.

Authors:  Jennifer M Sacheck; Akira Ohtsuka; S Christine McLary; Alfred L Goldberg
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-04-20       Impact factor: 4.310

7.  Changes in body composition and dietary intake induced by tumor necrosis factor alpha and corticosterone--individually and in combination.

Authors:  N Raina; K N Jeejeebhoy
Journal:  Am J Clin Nutr       Date:  1998-12       Impact factor: 7.045

8.  Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids.

Authors:  G Tiao; J Fagan; V Roegner; M Lieberman; J J Wang; J E Fischer; P O Hasselgren
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 9.  Glucocorticoid receptor physiology.

Authors:  Marjet D Heitzer; Irene M Wolf; Edwin R Sanchez; Selma F Witchel; Donald B DeFranco
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

10.  Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells.

Authors:  Arianna Dellavalle; Maurilio Sampaolesi; Rossana Tonlorenzi; Enrico Tagliafico; Benedetto Sacchetti; Laura Perani; Anna Innocenzi; Beatriz G Galvez; Graziella Messina; Roberta Morosetti; Sheng Li; Marzia Belicchi; Giuseppe Peretti; Jeffrey S Chamberlain; Woodring E Wright; Yvan Torrente; Stefano Ferrari; Paolo Bianco; Giulio Cossu
Journal:  Nat Cell Biol       Date:  2007-02-11       Impact factor: 28.824

View more
  71 in total

1.  Resveratrol prevents dexamethasone-induced expression of the muscle atrophy-related ubiquitin ligases atrogin-1 and MuRF1 in cultured myotubes through a SIRT1-dependent mechanism.

Authors:  Nima Alamdari; Zaira Aversa; Estibaliz Castillero; Aniket Gurav; Victoria Petkova; Steven Tizio; Per-Olof Hasselgren
Journal:  Biochem Biophys Res Commun       Date:  2011-12-07       Impact factor: 3.575

2.  Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle.

Authors:  Nima Alamdari; Ira J Smith; Zaira Aversa; Per-Olof Hasselgren
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-06-10       Impact factor: 3.619

3.  Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling.

Authors:  Taiyi Kuo; Michelle J Lew; Oleg Mayba; Charles A Harris; Terence P Speed; Jen-Chywan Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-25       Impact factor: 11.205

4.  Sepsis and glucocorticoids downregulate the expression of the nuclear cofactor PGC-1beta in skeletal muscle.

Authors:  Michael J Menconi; Zoltan P Arany; Nima Alamdari; Zaira Aversa; Patricia Gonnella; Patrick O'Neal; Ira J Smith; Steven Tizio; Per-Olof Hasselgren
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-07-20       Impact factor: 4.310

5.  Expression of Muscle-Specific Ribosomal Protein L3-Like Impairs Myotube Growth.

Authors:  Thomas Chaillou; Xiping Zhang; John J McCarthy
Journal:  J Cell Physiol       Date:  2016-01-14       Impact factor: 6.384

6.  Cardiac and vascular atrogin-1 mRNA expression is not associated with dexamethasone efficacy in the monocrotaline model of pulmonary hypertension.

Authors:  Michael L Paffett; Meghan M Channell; Jay S Naik; Selita N Lucas; Matthew J Campen
Journal:  Cardiovasc Toxicol       Date:  2012-09       Impact factor: 3.231

7.  Expression of glucocorticoid-induced leucine zipper (GILZ) in cardiomyocytes.

Authors:  David C Aguilar; Josh Strom; Beibei Xu; Kyle Kappeler; Qin M Chen
Journal:  Cardiovasc Toxicol       Date:  2013-06       Impact factor: 3.231

8.  p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting.

Authors:  J M McClung; A R Judge; S K Powers; Z Yan
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-02       Impact factor: 4.249

Review 9.  Metabolic functions of glucocorticoid receptor in skeletal muscle.

Authors:  Taiyi Kuo; Charles A Harris; Jen-Chywan Wang
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

10.  Opposite roles of myocardin and atrogin-1 in L6 myoblast differentiation.

Authors:  Yulan Jiang; Pavneet Singh; Hao Yin; Yi-Xia Zhou; Yu Gui; Da-Zhi Wang; Xi-Long Zheng
Journal:  J Cell Physiol       Date:  2013-10       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.